Respiratory | Napp Pharmaceuticals

Contact us

REQUEST A REPRESENTATIVE

Your browser is not supported.

To view this content, please use one of the following browsers:

Microsoft Edge
Chrome
Safari

image

event image

therapy icon

Differences between DPI and pMID inhalers

Differences between DPI and pMID inhalers

English

06:15

Asthma Talks

Respiratory

Respiratory

Dr Justus de Zeeuw

Dr de Zeeuw discussed the differences between DPI and pMID inhalers in this asthma talk video.

Dr Justus de Zeeuw

Head of Pneumology, Rehabilitation Clinic AmKaRe, Germany

Prescribing information for Flutiform fluticasone propionate/formoterol

Asthma management during COVID and beyond

Asthma management during COVID and beyond

English

09:16

Asthma Talks

Respiratory

Respiratory

Dr Justus de Zeeuw

Dr Zeeuw shares best practise in asthma management during COVID and beyond.

Dr Justus de Zeeuw

Head of Pneumology, Rehabilitation Clinic AmKaRe, Germany

Prescribing information for Flutiform fluticasone propionate/formoterol

Header image breathing difficulties

The ongoing dilemma of phenotyping vs stepping up or down in asthma therapy

Job Code :

JOB CODE: UK-INV-2200045 | DOP: March 2024

Respiratory

Prescribing information for Flutiform

frame 6

How can primary care professionals reduce the burden of asthma exacerbations and improve asthma control in the real world?

Job Code :

JOB CODE: UK-INV-2200045 | DOP: March 2024

Respiratory

Prescribing information for Flutiform

Optimising referral criteria to specialty care in severe asthma

Job Code :

JOB CODE: UK-INV-2200045 | DOP: November 2022

Respiratory

Prescribing information for Flutiform

pain management

Expert Opinion

Respiratory

pain management

Asthma Unmet Needs

Respiratory

INHALER

Read more about INHALER

EVIDENCE

Read more about EVIDENCE

TOLERABILITY

Read more about TOLERABILITY

Subscribe to Respiratory

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or drugsafetyUKandROI@mundipharma.com.